Anokion Announces Exclusive Strategic Collaboration with Celgene to Develop Novel Tolerance-Inducing Therapeutics for Autoimmune Diseases
News
January 9, 2017
LAUSANNE, Switzerland, and CAMBRIDGE, MA January 9, 2017
Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the formation of an exclusive global research collaboration with Celgene Switzerland LLC, an affiliate of Celgene Corp.